1. Home
  2. VERV

as 06-18-2024 9:30am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Founded: 2018 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 523.1M IPO Year: 2021
Target Price: $32.43 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.87 EPS Growth: N/A
52 Week Low/High: $4.90 - $21.04 Next Earning Date: 08-08-2024
Revenue: $16,049,000 Revenue Growth: 379.79%
Revenue Growth (this year): 32.56% Revenue Growth (next year): -40.51%

VERV Daily Stock ML Predictions

Stock Insider Trading Activity of Verve Therapeutics Inc. (VERV)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Ashe Andrew D. VERV See Remarks May 14 '24 Buy $6.26 76,000 $475,760.00 342,509 SEC Form 4
Nickerson Joan VERV Chief Administrative Officer Apr 1 '24 Sell $8.24 1,514 $12,475.36 8,659 SEC Form 4
Yeshwant Krishna VERV Director10% Owner Dec 1 '23 Buy $10.00 1,800,000 $18,000,000.00 1,800,000 SEC Form 4
Dorval Allison VERV Chief Financial Officer Nov 29 '23 Sell $11.45 554 $6,343.30 4,060 SEC Form 4

Share on Social Networks: